ストックスクリーナーアプリを入手
53.50
3.10%
1.61
プレマーケット:
53.55
0.05
+0.09%
前日終値:
$51.89
開ける：
$51.89
24時間の取引高:
1.54M
Relative Volume:
1.37
時価総額：
$4.38B
収益：
-
当期純損益:
$-153.72M
株価収益率:
-26.75
EPS:
-2
ネットキャッシュフロー:
$-103.81M
1週間 パフォーマンス:
+10.45%
1か月 パフォーマンス:
+27.32%
6か月 パフォーマンス:
+133.12%
1年 パフォーマンス:
+211.59%
1日の値動き範囲:
$50.86
$54.00
1週間の範囲:
$48.50
$55.42
52週間の値動き範囲:
$11.39
$55.42
Verona Pharma Plc Adr Stock (VRNA) Company Profile
名前
Verona Pharma Plc Adr
セクター
電話
011-44-0-2032834200
住所
3 MORE LONDON RIVERSIDE, LONDON
VRNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
53.50 | 4.38B | 0 | -153.72M | -103.81M | -2.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | 開始されました | ROTH MKM | Buy |
| 2024-10-03 | 開始されました | Wells Fargo | Overweight |
| 2023-05-22 | 再開されました | Jefferies | Buy |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-08-26 | 開始されました | Piper Sandler | Overweight |
| 2021-09-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-08-25 | 開始されました | Jefferies | Buy |
| 2020-08-10 | 開始されました | Canaccord Genuity | Buy |
| 2019-04-18 | 開始されました | BTIG Research | Buy |
すべてを表示
Verona Pharma Plc Adr (VRNA) 最新ニュース
Bronchiectasis Market to Show Positive Growth at a CAGR of 13.7% by 2034 | DelveInsight - GlobeNewswire Inc.
Looking For A Top Momentum Pick? Why Valley National Bancorp (NASDAQ: VLY) Is A Great Choice - Stocks Register
Hertz Global Holdings Inc (NASDAQ: HTZ): Overvalued Compared To Others? - Stocks Register
Verona Pharma Plc ADR (VRNA) Outlook: Looking Back For Insights - Stocks Register
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 19% This Week - Yahoo! Voices
Verona Pharma stock target increased, keeps buy on Q4 sales By Investing.com - Investing.com South Africa
Verona Pharma stock soars to all-time high of $49.05 - Investing.com India
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Verona Pharma stock soars to all-time high of $43.76 - Investing.com
Verona Pharma CFO Mark Hahn sells shares worth $4.4 million - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $4.36 million - Investing.com
Verona Pharma's CFO Mark Hahn sells shares worth $566,821 - Investing.com India
Verona Pharma's CFO Mark Hahn sells shares worth $566,821 By Investing.com - Investing.com South Africa
Verona Pharma CEO David Zaccardelli sells shares worth $627,233 - Investing.com
Verona Pharma CFO sells shares totaling $12,000 - Investing.com India
Verona Pharma's chief medical officer sells $1.18 million in shares - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $8,000 - Investing.com
Verona Pharma director David Ebsworth buys $88,800 in shares - Investing.com India
Verona Pharma director Christina Ackermann acquires $198,385 in shares - Investing.com
Verona Pharma CFO Mark Hahn sells shares worth $568,386 - Investing.com
Verona Pharma CEO David Zaccardelli sells $618,657 in shares - Investing.com
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre By Investing.com - Investing.com Nigeria
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre - Investing.com India
Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday - Investing.com Nigeria
Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday By Investing.com - Investing.com South Africa
Verona Pharma ADR earnings matched, revenue topped estimates By Investing.com - Investing.com UK
Verona Pharma CFO Mark Hahn sells shares worth $632,760 - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $633,895 - Investing.com India
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart
5 Biotech Stocks Likely To Outperform As Industry Prospects Look Bright - Barchart
Verona Pharma CEO David Zaccardelli sells $2.25 million in shares - Investing.com India
Verona Pharma CEO David Zaccardelli sells $2.25 million in shares By Investing.com - Investing.com South Africa
Verona Pharma CFO Mark Hahn sells shares worth $2.3 million By Investing.com - Investing.com South Africa
Verona Pharma CFO Mark Hahn sells shares worth $2.3 million - Investing.com India
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance
Market Insights: Verona Pharma Plc ADR (VRNA)’s Notable Drop of -0.55, Closing at 34.07 - The Dwinnex
Verona Pharma Plc ADR [VRNA] Insider Activity: An Update for Investors - Knox Daily
Phathom Pharmaceuticals Inc [PHAT] Investment Appeal on the Rise - Knox Daily
Verona Pharma Plc ADR (VRNA) stock: A year of ups and downs - US Post News
VRNA Shares Experience Decline in Value - Knox Daily
Financial Metrics Exploration: Understanding Verona Pharma Plc ADR (VRNA) Through Ratios - The Dwinnex
A stock that deserves closer examination: Verona Pharma Plc ADR (VRNA) - US Post News
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Wells Fargo gives an Overweight recommendation for Verona Pharma Plc ADR (VRNA) - Knox Daily
Verona Pharma Plc ADR’s (NASDAQ: VRNA) Stock Forecast: Increase To $38 In A Year - Stocks Register
Prepare Yourself for Liftoff: Verona Pharma Plc ADR (VRNA) - SETE News
Verona Pharma Plc ADR [VRNA] stock for 2,254,320 USD was sold by ZACCARDELLI DAVID - Knox Daily
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains? - Yahoo Finance
Cactus Inc [WHD] Records 50-Day SMA of $59.34 - Knox Daily
Verona Pharma stock soars to all-time high of $30.76 By Investing.com - Investing.com South Africa
Piper Sandler maintains Overweight rating on Verona Pharma shares By Investing.com - Investing.com South Africa
Verona Pharma Plc Adr (VRNA) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):